ArticleAsian Pacific journal of cancer prevention : APJCP2025
Introduction of the HPV Vaccine among Young Girls to Reduce the Long-Term Risk of Cervical Cancer in Eswatini: Programmatic Decision and Roll Out.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comment on: Introduction of the HPV Vaccine among Young Girls to Reduce the Long-Term Risk of Cervical Cancer in Eswatini.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Predictors of survival among cervical cancer patients in Swaziland (Eswatini): A population-based analysis in a resource-limited setting (2016-2024).PLOS global public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical cancer is a significant public health concern in Eswatini. In June 2023, the Eswatini government launched a national school based vaccination program aimed at administering two doses of the human papillomavirus (HPV) vaccine to adolescent girls, with the second dose administered six months after the first.
objectiveThis study seeks to assess the feasibility of school based HPV vaccination introduction campaign for prevention of cervical cancer among women in the Kingdom of Eswatini in Africa. The lessons learned, and challenges faced during the implementation of the national HPV vaccination program designed to prevent HPV infection are documented to improve HPV vaccination campaign in Africa.
methodsThe review study details the planning and execution of the HPV vaccination initiative within Eswatini's school based campaign, targeting 82,400 girls aged 9-14 years from 12 to 23 June 2023 schooldays.
resultsThe national goal was to vaccinate 82,400 girls. The campaign achieved a national coverage rate of 55.9%, with 46,512 girls successfully vaccinated. The Manzini region recorded the highest coverage at 60.1%, while the Shiselweni region had the lowest at 48.2%.
conclusionsThe introduction of the large-scale HPV vaccination campaign in schools proved successful. However, challenges such as misconceptions about eligibility criteria and misinformation persisted, impacting vaccine uptake and coverage. Continued efforts in community mobilization, public education on eligibility, and integration with healthcare services are essential for sustaining the program. Strengthening partnerships and mobilizing resources will also be critical for its long-term success.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.